BLATOPICALGEL
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
REGRANEX (becaplermin gel 0.01%) by Smith and Nephew. Approved for human platelet-derived growth factor [epc]. First approved in 1997.
Drug data last refreshed 22h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REGRANEX is a topical gel containing becaplermin, a recombinant human platelet-derived growth factor (PDGF) approved for diabetic foot ulcers. It promotes wound healing by stimulating tissue granulation and epithelialization at the application site. The drug represents a biologic approach to chronic wound management in patients with lower-extremity neuropathic ulcers.
$8MPart D
LOE ApproachingWith LOE approaching and modest Part D spending, the brand is in defensive mode; commercial teams will focus on payer retention and managed care rather than aggressive growth expansion.
Mechanism of Action
Pharmacologic Class:
Human Platelet-derived Growth Factor
Indications (1)
Clinical Trials (1)
A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX
Started Dec 2000
84 enrolled
Foot UlcerDiabetic FootSkin Ulcer+1 more
Why This Matters for Your Career
Worked on REGRANEX at Smith and Nephew? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.